KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Revenue (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Revenue for 17 consecutive years, with $12.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 1.3% to $12.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 billion, a 0.22% change, with the full-year FY2025 number at $48.2 billion, changed 0.22% from a year prior.
  • Revenue was $12.5 billion for Q4 2025 at Bristol Myers Squibb, up from $12.2 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $12.5 billion in Q4 2025 to a low of $11.0 billion in Q3 2023.
  • A 5-year average of $11.7 billion and a median of $11.7 billion in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: grew 15.54% in 2021, then fell 5.6% in 2025.
  • Bristol Myers Squibb's Revenue stood at $12.0 billion in 2021, then decreased by 4.83% to $11.4 billion in 2022, then rose by 0.62% to $11.5 billion in 2023, then rose by 7.54% to $12.3 billion in 2024, then rose by 1.3% to $12.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Revenue are $12.5 billion (Q4 2025), $12.2 billion (Q3 2025), and $12.3 billion (Q2 2025).